Skip to main content
NCBI home page
Springer logoLink to Springer
. 2025 Sep 11;26(6):1065. doi: 10.1007/s40257-025-00976-2

Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

Brett King 1, Jennifer Soung 2, Christos Tziotzios 3, Lidia Rudnicka 4, Pascal Joly 5, Melinda Gooderham 6, Rodney Sinclair 7, Natasha A Mesinkovska 8, Carle Paul 9, Yankun Gong 10, Susan D Anway 11, Helen Tran 10, Robert Wolk 11, Samuel H Zwillich 11, Alexandre Lejeune 12,✉
PMCID: PMC12615554  PMID: 40952573

Correction to: American Journal of Clinical Dermatology (2024) 25:299–314 10.1007/s40257-024-00846-3

In Supplementary file2, Table S8, under “Urticarias”, “Duration, median (range), weeks” has been corrected to “Duration, median (range), days”

The original article has been corrected.

Articles from American Journal of Clinical Dermatology are provided here courtesy of Springer

RESOURCES